Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naive glioblastoma.

ABSTRACT:

Background

A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in response to therapy is commonly observed; however, how tumor heterogeneity is reflected in individual drug sensitivities in the treatment-naïve glioblastoma stem cells (GSC) is unclear.

Methods

We cultured 12 patient-derived primary GBMs as tumorspheres and validated tumor stem cell properties by functional assays. Using automated high-throughput screening (HTS), we evaluated sensitivity to 461 anticancer drugs in a collection covering most FDA-approved anticancer drugs and investigational compounds with a broad range of molecular targets. Statistical analyses were performed

SUBMITTER: Skaga E 

PROVIDER: S-EPMC6593575 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature